JP2010514682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514682A5 JP2010514682A5 JP2009543160A JP2009543160A JP2010514682A5 JP 2010514682 A5 JP2010514682 A5 JP 2010514682A5 JP 2009543160 A JP2009543160 A JP 2009543160A JP 2009543160 A JP2009543160 A JP 2009543160A JP 2010514682 A5 JP2010514682 A5 JP 2010514682A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocycloalkyl
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 11
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- -1 antipsychotic Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 239000000841 delta opiate receptor agonist Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87096406P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/088036 WO2008079838A1 (en) | 2006-12-20 | 2007-12-19 | Compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514682A JP2010514682A (ja) | 2010-05-06 |
| JP2010514682A5 true JP2010514682A5 (enExample) | 2010-12-16 |
Family
ID=39562910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543160A Pending JP2010514682A (ja) | 2006-12-20 | 2007-12-19 | 化合物及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100093699A1 (enExample) |
| EP (1) | EP2120563A4 (enExample) |
| JP (1) | JP2010514682A (enExample) |
| CN (1) | CN101616585A (enExample) |
| WO (1) | WO2008079838A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009151393A1 (en) * | 2008-06-14 | 2009-12-17 | Astrazeneca Ab | Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders |
| BRPI0818376A2 (pt) | 2007-10-24 | 2015-04-14 | Dow Agrosciences Llc | Processo aperfeiçoado para a fabricação dos ésteres do ácido (r)-(+)-2-(4-(4-ciano-2-fluorofenóxi) fenóxi propiônico |
| EP2519101B1 (en) | 2009-12-31 | 2015-08-19 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| SI2544536T1 (sl) | 2010-03-11 | 2019-03-29 | Kempharm, Inc. | Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN110878048B (zh) * | 2018-09-06 | 2023-03-17 | 中国科学院上海药物研究所 | 作为防治精神障碍疾病的苯胺类化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| JPH0565257A (ja) * | 1991-07-05 | 1993-03-19 | Hokuriku Seiyaku Co Ltd | 多環式化合物及びその用途 |
| WO2004076431A1 (en) * | 2003-02-22 | 2004-09-10 | Teva Pharmaceutical Industries Ltd. | Synthesis of quetiapine and pharmaceutically acceptable salts thereof |
| US20060217366A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating schizophrenia and other disorders |
| DE602004028739D1 (de) * | 2003-07-02 | 2010-09-30 | Astrazeneca Ab | Metabolit von quetiapine |
| US20060063754A1 (en) * | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| US20070105836A1 (en) * | 2005-10-31 | 2007-05-10 | Lars Pettersson | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
-
2007
- 2007-12-19 CN CN200780051537A patent/CN101616585A/zh active Pending
- 2007-12-19 JP JP2009543160A patent/JP2010514682A/ja active Pending
- 2007-12-19 WO PCT/US2007/088036 patent/WO2008079838A1/en not_active Ceased
- 2007-12-19 US US12/520,133 patent/US20100093699A1/en not_active Abandoned
- 2007-12-19 EP EP07855245A patent/EP2120563A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540637A5 (enExample) | ||
| CN1060775C (zh) | 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物 | |
| JP5337054B2 (ja) | ムスカリン受容体アンタゴニストとベータ−２−アドレナリン受容体アゴニストの組み合わせ | |
| EA036446B1 (ru) | Соединения и композиции для подавления активности shp2 | |
| JP2014526435A5 (enExample) | ||
| JP2016169231A (ja) | Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法 | |
| RU2012141706A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств в отношении метаботропных глутаматных рецепторов-842 | |
| JP2010531292A5 (ja) | １１−ピペラジン−１−イルジベンゾ[ｂ,ｆ][１,４]チアゼピンの誘導体及びその使用 | |
| JP2010514682A5 (enExample) | ||
| JP2013519684A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 | |
| TWI568733B (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| JP2016527263A (ja) | ブロモドメイン阻害剤としての新規キナゾリノン | |
| JP2008513498A5 (enExample) | ||
| TW201920166A (zh) | 二氫吡咯並吡啶衍生物 | |
| JP2016507581A (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| CN108883110A (zh) | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 | |
| TW201831460A (zh) | 雜芳基苯氧基苯甲醯胺kappa類鴉片配體 | |
| JP2019537581A5 (enExample) | ||
| JP2016531880A (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
| JP2005508969A5 (enExample) | ||
| JP2007509960A (ja) | イミダゾ［１，２−ａ］ピリジン抗不安薬 | |
| JP2010514683A5 (enExample) | ||
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| KR20180101568A (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| RS52703B (sr) | Derivat dibenzotiazepina i njegova upotreba |